Humacyte Inc (NASDAQ: HUMA) closed the day trading at $2.99 down -1.64% from the previous closing price of $3.04. In other words, the price has decreased by -$0.0500 from its previous closing price. On the day, 1281538 shares were traded.
Ratios:
For a better understanding of HUMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 4.29 whereas as Long-Term Debt/Eq ratio is at 4.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 11, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
On August 14, 2023, Piper Sandler Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $2.75 to $3.50.
On June 22, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on June 22, 2023, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 14 ’23 when Dougan Brady W sold 2,000,000 shares for $2.78 per share. The transaction valued at 5,560,000 led to the insider holds 6,191,140 shares of the business.
Niklason Laura E sold 2,000,000 shares of HUMA for $5,560,000 on Sep 14 ’23. The President, CEO and Director now owns 6,191,140 shares after completing the transaction at $2.78 per share. On Aug 21 ’23, another insider, Ayabudge LLC, who serves as the 10% Owner of the company, sold 602,443 shares for $3.39 each. As a result, the insider received 2,042,282 and left with 8,191,140 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 362.01M and an Enterprise Value of 339.07M.
Stock Price History:
Over the past 52 weeks, HUMA has reached a high of $5.60, while it has fallen to a 52-week low of $1.96. The 50-Day Moving Average of the stock is 3.5396, while the 200-Day Moving Average is calculated to be 3.0716.
Shares Statistics:
Over the past 3-months, HUMA traded about 1.00M shares per day on average, while over the past 10 days, HUMA traded about 1.08M shares per day. A total of 103.67M shares are outstanding, with a floating share count of 86.14M. Insiders hold about 27.66% of the company’s shares, while institutions hold 14.95% stake in the company. Shares short for HUMA as of Mar 15, 2024 were 3.78M with a Short Ratio of 3.98, compared to 6.56M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.23% and a Short% of Float of 4.95%.
Earnings Estimates
Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.24, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.22 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.87 and -$0.92 for the fiscal current year, implying an average EPS of -$0.9. EPS for the following year is -$0.75, with 5 analysts recommending between -$0.62 and -$0.84.
Revenue Estimates
Based on 5 analysts’ estimates, the company’s revenue will be $30.85M in the next fiscal year. The high estimate is $42.6M and the low estimate is $12.53M. The average revenue growth estimate for next year is up 849.20% from the average revenue estimate for this year.
